ArticleInternational journal of women's dermatology2025
Contribution of the combined oral contraceptive ethinylestradiol 20 µg/dienogest 2 mg, in the treatment of mild to moderate acne vulgaris and its perceived psychological effects in young university women.
Article in International journal of women's dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In adult females, acne is usually a chronic condition, and its management remains challenging due to therapeutic failures or limited healthcare seeking, with repercussions on mental health. Oral contraceptives may provide an alternative to reduce acne and enhance psychological well-being. Objective: To identify the change in the severity of acne in young university women who used the combined oral contraceptive pills of ethinylestradiol 20 µg/dienogest 2 mg, and its perceived psychological effects on self-esteem, social relations, and noncontraceptive benefits. Methods: A prospective cohort was conducted between 2015 and 2016. Photographic monitoring of acne lesions was performed at 3, 6, 9, and 12 months after the start of the study. The photographs were evaluated by 2 specialists in dermatology, who established the degree of acne. Information was gathered regarding the perception of acne progression, the improvement of self-esteem, and noncontraceptive benefits. A descriptive analysis was performed. Results: In total, 86 women were included. At 6-month follow-up, the percentage of mild comedonal acne changed from 5.8 to 37.8%. At 12 months, at least 35% of the women had no acne lesions, and 43% were classified with mild comedonal acne. Results above 68% indicated that there was a favorable perception in the improvement of self-esteem, and the participants recognized that these changes improved their social relations (first month: 58.6% to sixth month: 90.5%). Limitations: A locally applied acne severity scale was employed, as it provides detailed lesion characterization but restricts comparability with other studies, and a lack of standardized scales for measuring perceived psychological and non-contraceptive benefits. Conclusion: Young women with acne who use oral contraceptives with dienogest and ethinyl estradiol obtain the additional benefit of reducing acne severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.